Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Sun Young ChoKorean Network for Study on Infectious Diseases

Abstract

Despite the remarkable emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and non-ST131 clones. Multivariate analysis revealed that older age (odds ratio [OR]=5.39, 95% confidence interval [CI] 1.22-23.89; p=0.027), nosocomial infection (OR=4.81, 95% CI 1.15-20.15; p=0.032), and higher Pitt bacteremia scor...Continue Reading

References

Dec 14, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Hélène Nicolas-ChanoineJames R Johnson
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G M RossoliniC Mugnaioli
Mar 13, 2008·The Journal of Antimicrobial Chemotherapy·Olivier ClermontGuillaume Arlet
May 17, 2008·Diagnostic Microbiology and Infectious Disease·Kwan Soo KoNam Yong Lee
Jan 12, 2010·International Journal of Antimicrobial Agents·Gisele Peirano, Johann D D Pitout
Nov 18, 2010·The Journal of Antimicrobial Chemotherapy·Benjamin A RogersDavid L Paterson
Nov 17, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Emilia TitelmanChristian G Giske
Nov 2, 2012·Scandinavian Journal of Infectious Diseases·Cheol-In KangJong Kyun Lee
Mar 8, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ritu BanerjeeJames R Johnson
Sep 12, 2013·PloS One·Marie-Hélène Nicolas-ChanoineUNKNOWN Coli β study group

❮ Previous
Next ❯

Citations

Apr 21, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Min Kyeong ChaJae-Hoon Song
Jun 30, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ji Young ParkHoan Jong Lee
Sep 2, 2017·Korean journal of pediatrics·Ki Wook YunIn Seok Lim
Jul 28, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Masoumeh RasoulinasabMohammad Mehdi Aslani

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.